PDF(Pubmed)
Abstract：
Studies have demonstrated the potential of mesenchymal stem cell (MSC) administration to promote functional recovery in preclinical studies of multiple sclerosis (MS), yet the effects of MSCs on remyelination are poorly understood. We wished to evaluate the therapeutic effects of MSCs on functional and histopathological outcomes in MS; therefore, we undertook an updated systematic review and meta-analysis of preclinical data on MSC therapy for MS. We searched mainstream databases from inception to July 15, 2021. Interventional studies of therapy using naïve MSCs in in vivo rodent models of MS were included. From each study, the clinical score was extracted as the functional outcome, and remyelination was measured as the histopathological outcome. Eighty-eight studies published from 2005 to 2021 met the inclusion criteria. Our results revealed an overall positive effect of MSCs on the functional outcome with a standardized mean difference (SMD) of -1.99 (95% confidence interval (CI): -2.32, -1.65; p = 0.000). MSCs promoted remyelination by an SMD of -2.31 (95% CI: -2.84, -1.79; p = 0.000). Significant heterogeneity among studies was observed. Altogether, our meta-analysis indicated that MSC administration improved functional recovery and promoted remyelination prominently in rodent models of MS.
摘要：
研究表明，在多发性硬化症（MS）的临床前研究中，间充质干细胞（MSC）给药促进功能恢复的潜力，然而MSCs对髓鞘再生的影响尚不清楚.我们希望评估MSCs对MS的功能和组织病理学结果的治疗效果；因此，我们对MSC治疗MS的临床前数据进行了最新的系统评价和荟萃分析。我们搜索了从成立到2021年7月15日的主流数据库。包括在MS的体内啮齿动物模型中使用初始MSC进行治疗的介入研究。从每一项研究中，提取临床评分作为功能结果，和髓鞘再生被测量为组织病理学结果。2005年至2021年发表的88项研究符合纳入标准。我们的结果表明，MSCs对功能结局的总体积极影响，标准化平均差（SMD）为-1.99（95％置信区间（CI）：-2.32，-1.65；p=0.000）。MSCs通过-2.31的SMD促进髓鞘再生(95%CI:-2.84,-1.79;p=0.000)。观察到研究之间存在显著的异质性。总之,我们的荟萃分析表明，在MS的啮齿动物模型中，MSC的使用显着改善了功能恢复并促进了髓鞘再生。
